- In late June 2026, McKesson Corporation was added to the Russell 1000 Defensive, Russell 1000 Value-Defensive, and Russell 1000 Growth-Defensive indexes, while partner TempraMed expanded its distribution agreement with McKesson Medical-Surgical across North America to deepen access to temperature-controlled medication solutions.
- These developments highlight how McKesson is increasingly positioned as a core defensive healthcare distributor while extending its reach into specialized, higher-value medication handling through broader TempraMed integration.
- Next, we’ll examine how McKesson’s new defensive index inclusions and expanded TempraMed partnership may influence its existing investment narrative.
Uncover the next big thing with 22 elite penny stocks that balance risk and reward.
McKesson Investment Narrative Recap
To own McKesson, you generally need to believe in its role as a scale healthcare distributor with growing exposure to complex, higher-value pharmaceuticals and services. The new Russell defensive index inclusions and the broader TempraMed rollout do not materially change the near term focus on execution in specialty and oncology services or the key risk around policy-driven pressure on drug pricing and margins.
The TempraMed expansion across North America is most relevant here, because it ties directly into McKesson’s push into more complex cold chain and specialty medication handling, where operational capabilities can support its existing catalysts in specialty, oncology, and value-added services.
Yet investors should also weigh how rising regulatory scrutiny on drug pricing could affect McKesson’s margins and capital returns...
Read the full narrative on McKesson (it's free!)
McKesson's narrative projects $499.3 billion revenue and $6.1 billion earnings by 2029. This requires 7.4% yearly revenue growth and about a $1.3 billion earnings increase from $4.8 billion today.
Uncover how McKesson's forecasts yield a $941.40 fair value, a 25% upside to its current price.
Exploring Other Perspectives
Six fair value estimates from the Simply Wall St Community range from about US$2 to US$941 per share, underlining how far apart views on McKesson can be. Against that backdrop, understanding the risk that tighter drug pricing regulation could pressure margins and reshape expectations for its defensive profile becomes especially important as you compare these different viewpoints.
Explore 6 other fair value estimates on McKesson - why the stock might be worth less than half the current price!
Decide For Yourself
Don't just follow the ticker - dig into the data and build a conviction that's truly your own.
- A great starting point for your McKesson research is our analysis highlighting 5 key rewards and 1 important warning sign that could impact your investment decision.
- Our free McKesson research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate McKesson's overall financial health at a glance.
Want Some Alternatives?
Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:
- Explore 26 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
- Invest in the nuclear renaissance through our list of 89 elite nuclear energy infrastructure plays powering the global AI revolution.
- AI is about to change healthcare. These 40 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com